The EZH2 inhibitor tazemetostat (Tazverik) may mimic the role of the KDM6A gene in upregulating CD38 and CD48 expression, suggesting that this agent could restore responses to daratumamab (Darzalex) in patients with multiple myeloma, according to a presentation at the 20th International Myeloma Society Annual Meeting.1
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (œHUTCHMED) (Nasdaq/AIM:‹HCM; HKEX:‹13) today announces that it has completed patient...
Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as 'an Ipsen company' at deal close.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update.
Hutchmed has dosed the first participant in a bridging study of tazemetostat to treat relapsed/refractory follicular lymphoma (R/R FL) in China.
On Monday, the French biopharma said it had an agreement in place to acquire oncology specialist Epizyme for $247 million.
HONG KONG and SHANGHAI, China and FLORHAM PARK, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that TAZVERIK® ...
The workforce reduction and pipeline update was noted in a brief statement in the biotech's fourth-quarter earnings report Tuesday. The terminations are slated for the first quarter of 2022 with the company projecting savings of as much as $3.2 million. In a statement, Epizyme said the cuts were “spread across multiple areas of the business.”
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today presented updated safety and activity data from the Phase 1b portion of its Phase 1b/3 confirmatory study evaluating the investigational use of TAZVERIK® (tazemetostat), a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidomide (R2) in patients with relapsed/refractory follicular lymphoma (FL) who have been treated with at least one prior systemic therapy, including patients who are rituximab-refractory and/or POD24, at the 2021 American Society of Hematology (ASH) Annual Meeting.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today reported its third quarter 2021 financial results and business update.